Results 11 to 20 of about 14,200 (285)

Oxidation of Mesalamine under Phenoloxidase- or Peroxidase-like Enzyme Catalysis

Molecules, 2023
Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to better ...
Rimaz El Zein, Pompilia Ispas-Szabo, Maziar Jafari, Mohamed Siaj, Mircea Alexandru Mateescu   +4 more
doaj   +2 more sources

Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery

Gels, 2023
This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal, Rashad M. Kaoud, Shadeed Gad, Hatem I. Mokhtar, Abdullah Alattar, Reem Alshaman, Sawsan A. Zaitone, Yasser M. Moustafa, Taha M. Hammady   +8 more
doaj   +2 more sources

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment

Frontiers in Pharmacology, 2021
Mesalamine has been well used in the improvement of ulcerative colitis (UC) in clinics, however, the underlying mechanisms were not well illustrated. To explore its efficacy from the perspective of gut microbiota and related metabolites, we employed 16S ...
Liang Dai, Yingjue Tang, Wenjun Zhou, Yanqi Dang, Qiaoli Sun, Zhipeng Tang, Mingzhe Zhu, Mingzhe Zhu, Guang Ji   +8 more
doaj   +2 more sources

Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study [PDF]

Journal of Clinical Medicine, 2023
Background: Mesalamine is one of the most-used drugs in inflammatory bowel disease (IBD), especially ulcerative colitis. Regulatory agencies have listed mesalamine as an unsafe drug in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency ...
Maria Pina Dore, Giulia Tomassini, Chiara Rocchi, Milutin Bulajić, Monica Carta, Alessandra Errigo, A Dimaggio, Federica Padedda, Giovanni Mario Pes   +8 more
openalex   +2 more sources

Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

Journal of Investigative Surgery, 2023
Objective: This study is aimed at investigating the impact of mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules on intestinal mucosa barrier function and intestinal microbiota in mildly active Crohn’s disease
Meiqin Shen, Yingqi Shi, Zhenming Ge, Junbo Qian   +3 more
doaj   +2 more sources

Recurrent Pericarditis: A Rare Adverse Effect of Mesalamine [PDF]

Cureus, 2023
Inflammation of the myocardium (myocarditis), pericardium (pericarditis), or both (myopericarditis) is a rare but potentially lethal side effect of mesalamine, a drug widely used in the treatment of inflammatory bowel disease (IBD).
Pratul Karki, Ariya Kunwar, Nitish Sharma, Megha Dogra   +3 more
openalex   +2 more sources

A hydrogen-sulfide derivative of mesalamine reduces the severity of intestinal and lung injury in necrotizing enterocolitis through endothelial nitric oxide synthase

American Journal of Physiology. Regulatory Integrative and Comparative Physiology, 2022
PURPOSE Necrotizing enterocolitis (NEC) remains a devastating disease that affects preterm infants. Hydrogen sulfide (H2S) donors have been shown to reduce the severity of NEC, but the optimal compound has yet to be identified.
Brian D. Hosfield, Chelsea Hunter, Hongge Li, Natalie A. Drucker, Anthony R. Pecoraro, Krishna Manohar, W. Christopher Shelley, Troy A. Markel   +7 more
openalex   +3 more sources

The Use and Role of Mesalamine in the Treatment of Ulcerative Colitis: A Literature Review. [PDF]

Cureus
Chand S, Bendagiri Matam M, Bhatt NK, Neelakantan Ramaswamy S, Harikrishnan S, Agarwal Y, Mohammed L.   +6 more
europepmc   +3 more sources

Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis. [PDF]

J Pers Med
Pagnini C, Antonelli E, Scrivo B, Cappello M, Soncini M, Vassallo R, Mocci G, Di Paolo MC, On Behalf Of Aigo Ibd Commission.   +8 more
europepmc   +3 more sources

Design and validation of a robust stability-indicating reversed-phase HPLC method for quantification of mesalamine in formulated drug products. [PDF]

BMC Chem
Mishra AS, Vasanthan M.
europepmc   +3 more sources